Catalyst Dossier · compiled by CeliA 🧫

Amphastar Pharmaceuticals, Inc. (AMPH)

Pharmaceutical Preparations · market cap $829M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-06Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Epinephrine inhalation aerosol	Phase 3	Asthma
I004	Phase 3	Pharmacokinetics
Albuterol DPI 25 mcg/inh	Phase 2	Asthma
A006 DPI	Phase 2	Asthma
Epinephrine Inhalation Aerosol, HFA	Phase 2	Asthma
E004 (Epinephrine Inhalation Aerosol) HFA-MDI	Phase 3	Asthma
Proventil® MDI	Phase 2	Asthma
A006	Phase 2	Asthma
Arm T1: Primatene Mist HFA	Phase 2	Asthma
albuterol inhalation powder	Phase 2	Asthma
Epinephrine HFA-MDI (E004)	Phase 3	Asthma
Hyaluronidase	Phase 2	Allergic Skin Reaction
Primatene Mist	Phase 3	Asthma
NovoLog	Phase 3	Pharmacokinetics

Price & technical context

3-month

+2.6%

6-month

-25.0%

12-month

-12.5%

52-wk range

$16.87–$30.81

vs 50-day MA

+1.0%

vs 200-day MA

-15.1%

Realized vol

57.0%

Max drawdown

-68.4%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for AMPH (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 14 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.